Back to your search result

Description

A cell permeable, potent, and selective oxime PDE4D inhibitor (IC50 = 0.67 µ,M) which displays much reduced activities toward other PDE4 isoforms. It is shown to cause a significant 40% increase in extracellular cAMP in the hippocampus of freely moving rats in vivo at 100 µ,M, but has no effect on Abeta levels. This compound elicits cognitive enhancement in vivo at the optimum dose of 0.003 mg/kg in both mice and rat models, and unlike rolipram, does not cause emesis-like behavior in rodents.